Autolus Q2 net loss $58.3M; cash $705.9M; obe-cel PDUFA Nov 16, 2024 on track

Autolus Therapeutics plc

2024-Q2 EPS reported -$0.43 revenue$10,091,000

Net loss $58.3M ($0.22/sh) vs $45.6M ($0.26/sh) in Q2 2023; cash $705.9M up from $239.6M at Dec 31, 2023.
Obe-cel PDUFA target action date set at November 16, 2024; BLA under review by FDA.
FELIX data (median follow-up 21 mos): 40% of responders in ongoing remission without subsequent stem cell transplant.
MAA submitted to UK MHRA July 2024; EMA MAA accepted April 2024.
R&D expenses $36.6M, G&A $21.9M, both up on pre-commercialization activities and new manufacturing facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.